---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-134399"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:06:27.985304+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NextCure Q3 2021 net loss widens to $17.9M; cash position $235.3M

## Summary
- Net loss of $17.9M for Q3 2021 vs $16.4M in Q3 2020, driven by higher R&D and G&A costs.
- Cash, cash equivalents and marketable securities $235.3M at Sep 30, 2021, down $48.1M from Dec 31, 2020.
- R&D expenses $13.6M (up from $12.7M) and G&A $4.9M (up from $4.7M) year-over-year.
- Appointed Ellen G. Feigal and Anne Borgman to Board of Directors; added three new Scientific Advisory Board members.
- Cash runway expected to fund operations into second half of 2023.

## SEC filing metadata
- accession: 0001104659-21-134399
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/0001104659-21-134399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465921134399/tm2131564d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-134399
- JSON: https://secwatch.observer/filing/0001104659-21-134399.json
- Plain text: https://secwatch.observer/filing/0001104659-21-134399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.